X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs SUN PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA SUN PHARMA GSK PHARMA/
SUN PHARMA
 
P/E (TTM) x 59.9 15.9 375.8% View Chart
P/BV x 11.7 3.7 313.5% View Chart
Dividend Yield % 2.1 0.2 1,026.5%  

Financials

 GSK PHARMA   SUN PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-16
SUN PHARMA
Mar-16
GSK PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs3,8501,201 320.6%   
Low Rs2,966706 419.8%   
Sales per share (Unadj.) Rs332.3117.5 282.9%  
Earnings per share (Unadj.) Rs44.319.6 226.1%  
Cash flow per share (Unadj.) Rs47.223.8 198.4%  
Dividends per share (Unadj.) Rs50.001.00 5,000.0%  
Dividend yield (eoy) %1.50.1 1,399.1%  
Book value per share (Unadj.) Rs202.7130.5 155.4%  
Shares outstanding (eoy) m84.702,406.60 3.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x10.38.1 126.3%   
Avg P/E ratio x76.948.7 158.1%  
P/CF ratio (eoy) x72.240.1 180.2%  
Price / Book Value ratio x16.87.3 230.0%  
Dividend payout %112.95.1 2,211.8%   
Avg Mkt Cap Rs m288,6432,294,813 12.6%   
No. of employees `0004.614.7 31.3%   
Total wages/salary Rs m4,43447,971 9.2%   
Avg. sales/employee Rs Th6,104.519,169.8 31.8%   
Avg. wages/employee Rs Th961.63,253.0 29.6%   
Avg. net profit/employee Rs Th813.73,197.9 25.4%   
INCOME DATA
Net Sales Rs m28,148282,697 10.0%  
Other income Rs m1,2186,170 19.7%   
Total revenues Rs m29,366288,867 10.2%   
Gross profit Rs m4,77483,239 5.7%  
Depreciation Rs m24810,135 2.4%   
Interest Rs m04,769 0.0%   
Profit before tax Rs m5,74474,505 7.7%   
Minority Interest Rs m0-11,126 0.0%   
Prior Period Items Rs m0-19 0.0%   
Extraordinary Inc (Exp) Rs m26-6,852 -0.4%   
Tax Rs m2,0189,349 21.6%   
Profit after tax Rs m3,75247,159 8.0%  
Gross profit margin %17.029.4 57.6%  
Effective tax rate %35.112.5 280.0%   
Net profit margin %13.316.7 79.9%  
BALANCE SHEET DATA
Current assets Rs m21,462308,646 7.0%   
Current liabilities Rs m10,536132,477 8.0%   
Net working cap to sales %38.862.3 62.3%  
Current ratio x2.02.3 87.4%  
Inventory Days Days6883 81.6%  
Debtors Days Days1688 18.7%  
Net fixed assets Rs m4,717133,606 3.5%   
Share capital Rs m8472,407 35.2%   
"Free" reserves Rs m16,308266,909 6.1%   
Net worth Rs m17,171314,042 5.5%   
Long term debt Rs m1631,167 0.1%   
Total assets Rs m30,620542,196 5.6%  
Interest coverage xNM16.6-  
Debt to equity ratio x00.1 0.9%  
Sales to assets ratio x0.90.5 176.3%   
Return on assets %12.39.6 127.9%  
Return on equity %21.915.0 145.5%  
Return on capital %33.617.8 189.1%  
Exports to sales %014.0 0.1%   
Imports to sales %15.13.1 479.1%   
Exports (fob) Rs m439,572 0.0%   
Imports (cif) Rs m4,2378,882 47.7%   
Fx inflow Rs m51942,171 1.2%   
Fx outflow Rs m8,32021,583 38.5%   
Net fx Rs m-7,80120,588 -37.9%   
CASH FLOW
From Operations Rs m1,38667,694 2.0%  
From Investments Rs m5,010-44,549 -11.2%  
From Financial Activity Rs m-6,383-19,243 33.2%  
Net Cashflow Rs m123,902 0.3%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 5.1 198.8%  
FIIs % 23.8 23.0 103.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 8.3 185.5%  
Shareholders   102,036 133,026 76.7%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades in Green; Bank Stocks Witness Selling(01:30 pm)

After opening the day on a flat note, the Indian share markets have reversed the trend and are currently trading above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Sun Pharma: USFDA Observations Post Good Quarterly Performance (Quarterly Results Update - Detailed)

Dec 12, 2016

Sun Pharma has announced its September quarter (2QFY17) results. The company has reported 13.2% YoY growth in sales and a growth of 117% in the net profits. Here is our analysis of the results.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Aug 17, 2017 03:27 PM

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS